BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 2848111)

  • 21. [Kinetic analysis of glucose metabolism in meningiomas--comparison with malignant gliomas].
    Shioya H; Mineura K; Sasajima T; Kowada M; Iida H; Ogawa T; Hatazawa J; Uemura K
    No To Shinkei; 1995 Jun; 47(6):549-56. PubMed ID: 7605682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET.
    Roelcke U; Radü EW; von Ammon K; Hausmann O; Maguire RP; Leenders KL
    J Neurol Sci; 1995 Sep; 132(1):20-7. PubMed ID: 8523026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury.
    Ogawa T; Kanno I; Shishido F; Inugami A; Higano S; Fujita H; Murakami M; Uemura K; Yasui N; Mineura K
    Acta Radiol; 1991 May; 32(3):197-202. PubMed ID: 2064862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy.
    Goldman S; Levivier M; Pirotte B; Brucher JM; Wikler D; Damhaut P; Dethy S; Brotchi J; Hildebrand J
    J Nucl Med; 1997 Sep; 38(9):1459-62. PubMed ID: 9293808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDG hypermetabolism associated with inflammatory necrotic changes following radiation of meningioma.
    Fischman AJ; Thornton AF; Frosch MP; Swearinger B; Gonzalez RG; Alpert NM
    J Nucl Med; 1997 Jul; 38(7):1027-9. PubMed ID: 9225785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma.
    De Witte O; Levivier M; Violon P; Salmon I; Damhaut P; Wikler D; Hildebrand J; Brotchi J; Goldman S
    Neurosurgery; 1996 Sep; 39(3):470-6; discussion 476-7. PubMed ID: 8875476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the value of emission tomography studies in patients with a primary glioblastoma multiforme treated by 192Ir brachytherapy?
    Koot RW; Habraken JB; Hulshof MC; Paans AM; Bosch DA; Pruim J
    Acta Neurochir (Wien); 2008 Apr; 150(4):345-9. PubMed ID: 18278573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.
    Chung JK; Kim YK; Kim SK; Lee YJ; Paek S; Yeo JS; Jeong JM; Lee DS; Jung HW; Lee MC
    Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):176-82. PubMed ID: 11926379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole.
    Valk PE; Mathis CA; Prados MD; Gilbert JC; Budinger TF
    J Nucl Med; 1992 Dec; 33(12):2133-7. PubMed ID: 1334136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence.
    Spaeth N; Wyss MT; Weber B; Scheidegger S; Lutz A; Verwey J; Radovanovic I; Pahnke J; Wild D; Westera G; Weishaupt D; Hermann DM; Kaser-Hotz B; Aguzzi A; Buck A
    J Nucl Med; 2004 Nov; 45(11):1931-8. PubMed ID: 15534065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas.
    Gross MW; Weber WA; Feldmann HJ; Bartenstein P; Schwaiger M; Molls M
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):989-95. PubMed ID: 9719107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of survival in glioma patients by means of positron emission tomography.
    Patronas NJ; Di Chiro G; Kufta C; Bairamian D; Kornblith PL; Simon R; Larson SM
    J Neurosurg; 1985 Jun; 62(6):816-22. PubMed ID: 2987440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma.
    Deshmukh A; Scott JA; Palmer EL; Hochberg FH; Gruber M; Fischman AJ
    Clin Nucl Med; 1996 Sep; 21(9):720-5. PubMed ID: 8879874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography of fluorine-18-deoxyglucose and image-guided phosphorus-31 magnetic resonance spectroscopy in brain tumors.
    Heiss WD; Heindel W; Herholz K; Rudolf J; Bunke J; Jeske J; Friedmann G
    J Nucl Med; 1990 Mar; 31(3):302-10. PubMed ID: 2308001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas.
    Roelcke U; Blasberg RG; von Ammon K; Hofer S; Vontobel P; Maguire RP; Radü EW; Herrmann R; Leenders KL
    J Nucl Med; 1998 May; 39(5):879-84. PubMed ID: 9591593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose.
    Woesler B; Kuwert T; Morgenroth C; Matheja P; Palkovic S; Schäfers M; Vollet B; Schäfers K; Lerch H; Brandau W; Samnick S; Wassmann H; Schober O
    Eur J Nucl Med; 1997 Apr; 24(4):428-34. PubMed ID: 9096095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-[C-11]thymidine imaging of malignant brain tumors.
    Eary JF; Mankoff DA; Spence AM; Berger MS; Olshen A; Link JM; O'Sullivan F; Krohn KA
    Cancer Res; 1999 Feb; 59(3):615-21. PubMed ID: 9973209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.
    Hirata K; Terasaka S; Shiga T; Hattori N; Magota K; Kobayashi H; Yamaguchi S; Houkin K; Tanaka S; Kuge Y; Tamaki N
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):760-70. PubMed ID: 22307533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors.
    Marriott CJ; Thorstad W; Akabani G; Brown MT; McLendon RE; Hanson MW; Coleman RE
    J Nucl Med; 1998 Aug; 39(8):1376-80. PubMed ID: 9708511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET.
    Kim EE; Chung SK; Haynie TP; Kim CG; Cho BJ; Podoloff DA; Tilbury RS; Yang DJ; Yung WK; Moser RP
    Radiographics; 1992 Mar; 12(2):269-79. PubMed ID: 1561416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.